1
|
Keloid treatments: an evidence-based systematic review of recent advances. Syst Rev 2023; 12:42. [PMID: 36918908 PMCID: PMC10012475 DOI: 10.1186/s13643-023-02192-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2022] [Accepted: 02/15/2023] [Indexed: 03/16/2023] Open
Abstract
BACKGROUND Keloids are pathologic scars that pose a significant functional and cosmetic burden. They are challenging to treat, despite the multitude of treatment modalities currently available. OBJECTIVE The aim of this study was to conduct an evidence-based review of all prospective data regarding keloid treatments published between 2010 and 2020. METHODS A systematic literature search of PubMed (National Library of Medicine), Embase (Elsevier), and Cochrane Library (Wiley) was performed in November of 2020. Search strategies with the keywords "keloid" and "treatment" were performed by a medical librarian. The search was limited to prospective studies that were peer-reviewed, reported on clinical outcomes of keloid therapies, and were published in the English language between January 1, 2010, and November 24, 2020. RESULTS A total of 3462 unique citations were identified, of which 108 studies met inclusion criteria. Current literature supports silicone gel or sheeting with corticosteroid injections as first-line therapy for keloids. Adjuvant intralesional 5-fluorouracil (5-FU), bleomycin, or verapamil can be considered, although mixed results have been reported with each. Laser therapy can be used in combination with intralesional corticosteroids or topical steroids with occlusion to improve drug penetration. Excision of keloids with immediate post-excision radiation therapy is an effective option for recalcitrant lesions. Finally, silicone sheeting and pressure therapy have evidence for reducing keloid recurrence. CONCLUSIONS This review was limited by heterogeneity of subject characteristics and study outcome measures, small sample sizes, and inconsistent study designs. Larger and more robust controlled studies are necessary to further understand the variety of existing and emerging keloid treatments, including corticosteroids, cryotherapy, intralesional injections, lasers, photodynamic therapy, excision and radiation, pressure dressings, and others.
Collapse
|
2
|
Oliveira GV, Metsavaht LD, Kadunc BV, Jedwab SKK, Bressan MS, Stolf HO, Castro RG, Bezerra SMFMC, Calil DA, Addor FAZ, Fraga JCS, Reis CMS, Reis-Filho E, Silva MR, Ramos-E-Silva M, Hexsel DM. Treatment of keloids and hypertrophic scars. Position statement of the Brazilian expert group GREMCIQ. J Eur Acad Dermatol Venereol 2021; 35:2128-2142. [PMID: 34263958 DOI: 10.1111/jdv.17484] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Accepted: 05/31/2021] [Indexed: 12/23/2022]
Abstract
Keloids (K) and hypertrophic scars (HS) are abnormal responses to wound healing that occur as the result of dermal inflammation. Despite the advances on their treatment, many patients still suffer from the negative effects of excessive scarring; its approach is impaired by the lack of objective data on different treatments and the large genetic variability among patients and the difficulties in producing multicentre studies. Their incidence among the Brazilian population is high, as the result of an admixture of Amerindians, Europeans and Africans ancestral roots. With the aim of producing multicentre studies on K and HS, a panel of senior Brazilian dermatologists focused on their treatment was invited to contribute with the K and HS Treatment Brazilian Guidelines. In the first part of this study, different treatment modalities for keloids and HS are fully reviewed by the panel. The second part of the study presents a consensus recommendation of treatment for different types of lesions. More than a literature review, this article aims to show the pitfalls and pearls of each therapeutic option, as well as a therapeutic approach by the Panel of Experts on keloids and Scars on a highly mixed population, providing simple guidelines.
Collapse
Affiliation(s)
- G V Oliveira
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Mario Penna/Luxemburgo Hospital, Keloids and Scars Ambulatory, Belo Horizonte, Brazil
| | - L D Metsavaht
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Santa Casa de Misericórdia, Rio de Janeiro, Brazil
| | - B V Kadunc
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Surgical and Cosmetic Dermatology, São Paulo, Brazil
| | - S K K Jedwab
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Skinlaser Director, São Paulo, Brazil
| | - M S Bressan
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Maura Bressan Dermatology, Campinas, Brazil
| | - H O Stolf
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,UNICAMP, Campinas, Brazil
| | - R G Castro
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil
| | - S M F M C Bezerra
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Federal University of Pernambuco, Recife, Brazil
| | - D A Calil
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Brazilian Society of Dermatology, São Paulo Session, São Paulo, Brazil
| | - F A Z Addor
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Albert Einstein Hospital, São Paulo, Brazil
| | - J C S Fraga
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Military Hospital, Belo Horizonte, Brazil
| | - C M S Reis
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Dermatology Residency Program, ESCS-DF, Brasilia, Brazil
| | - E Reis-Filho
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Dermatology Residency Program, ESCS-DF, Brasilia, Brazil
| | | | - M Ramos-E-Silva
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,Dermatology Residency Program, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - D M Hexsel
- Brazilian Society of Dermatology and Dermatologic Surgery and GREMCIQ, Rio de Janeiro, Brazil.,International Society for Dermatologic Surgery (ISDS), Hexsel Dermatology Clinics and Brazilian Center for Studies in Dermatology, Porto Alegre, Brazil
| |
Collapse
|
3
|
Zawadiuk LRR, Van Slyke AC, Bone J, Redfern B, Carr NJ, Arneja JS. What Do We Know About Treating Recalcitrant Auricular Keloids? A Systematic Review and Meta-Analysis. Plast Surg (Oakv) 2021; 30:49-58. [PMID: 35096693 PMCID: PMC8793758 DOI: 10.1177/2292550321995746] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background: Recalcitrant auricular keloids are keloids that have recurred after any previous treatment. They have been shown to have an increased likelihood of recurrence. There is no consensus on how best to treat recalcitrant auricular keloids. Here, we perform the first systematic review and meta-analysis investigating the evidence for treating recalcitrant auricular keloids. Methods: We searched MEDLINE, EMBASE, CINAHL, and EBM Reviews using specific keywords. Prespecified inclusion and exclusion criteria were used to assess article eligibility. Data were extracted for number of recalcitrant keloids, treatment modality, recurrence, and minimum follow-up time. Included articles were stratified by treatment and assigned a level of evidence (LOE) based on the Oxford Centre for Evidence-Based Medicine guidelines. A meta-analysis was performed to estimate recurrence rates with 95% confidence intervals for each treatment modality. Results: A total of 887 unique articles were identified and 13 included. Eleven were LOE III and 2 were LOE IV. Recurrence rates were found to be 9% (95% CI: 3%-25%) for excision with adjuvant brachytherapy, 14% (95% CI: 12%-17%) for excision with adjuvant compression therapy, 17% (95% CI: 3%-56%) for excision with adjuvant external beam radiation, and 18% (95% CI: 4%-53%) for excision with adjuvant steroid injections. No statistical significant difference was found. Conclusions: Data for treatment of auricular keloids are heterogeneous with few high-quality studies. Excision with adjuvant brachytherapy has the lowest recurrence rate in our analysis. Narrow confidence intervals reported here for brachytherapy and compression therapy may help surgeons more confidently recommend either of these treatment modalities to patients.
Collapse
Affiliation(s)
- Luke R. R. Zawadiuk
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Aaron C. Van Slyke
- Division of Plastic Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jeffrey Bone
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Baillie Redfern
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Nicholas J. Carr
- Division of Plastic Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jugpal S. Arneja
- Division of Plastic Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
6
|
Bao Z, Gao P, Xia G, Wang Z, Kong M, Feng C, Cheng X, Liu Y, Chen X. A thermosensitive hydroxybutyl chitosan hydrogel as a potential co-delivery matrix for drugs on keloid inhibition. J Mater Chem B 2016; 4:3936-3944. [DOI: 10.1039/c6tb00378h] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A thermosensitive hydroxybutyl chitosan hydrogel could be used as a potential co-delivery matrix for drugs on keloid inhibition.
Collapse
Affiliation(s)
- Zixian Bao
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Ping Gao
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Guixue Xia
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Zhiguo Wang
- Department of Plastic Surgery
- The Affiliated Hospital of Medical College Qingdao University
- Qingdao 266013
- China
| | - Ming Kong
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Chao Feng
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Xiaojie Cheng
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Ya Liu
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| | - Xiguang Chen
- College of Marine Life Science
- Ocean University of China
- Qingdao 266003
- China
| |
Collapse
|